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BACKGROUND: Oral contraceptive use and reproductive factors may initiate long-term changes to the hormonal milieu and thereby,
possibly influence colorectal cancer risk.
METHODS: We examined the association of hormonal and reproductive factors with risk of colorectal cancer among 337802 women
in the European Prospective Investigation into Cancer and Nutrition, of whom 1878 developed colorectal cancer.
RESULTS: After stratification for center and age, and adjustment for body mass index, smoking, diabetes mellitus, physical activity and
alcohol consumption, ever use of oral contraceptives was marginally inversely associated with colorectal cancer risk (hazard ratio
(HR), 0.92; 95% confidence interval (CI), 0.83–1.02), although this association was stronger among post-menopausal women
(HR, 0.84; 95% CI: 0.74–0.95). Duration of oral contraceptive use and reproductive factors, including age at menarche, age at
menopause, type of menopause, ever having an abortion, parity, age at first full-term pregnancy and breastfeeding, were not
associated with colorectal cancer risk.
CONCLUSION: Our findings provide limited support for a potential inverse association between oral contraceptives and colorectal cancer risk.
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yMen tend to have a slightly higher incidence of colorectal
cancer than women of similar age (American Cancer Society,
2007). Oestrogen has been implicated for this decreased risk
in women through mechanisms that involve reduction of
secondary bile acid production (McMichael and Potter, 1980;
Bayerdorffer et al, 1995), reduction of circulating insulin-like
growth factor-I (Campagnoli et al, 1993; Renehan et al, 2004),
and protection of the oestrogen receptor gene from methylation
(Issa et al, 1994).
The epidemiologic evidence for a causal link between oral
contraceptives and colorectal cancer risk is equivocal. Some
studies have suggested inverse associations (Potter and McMi-
chael, 1983; Martinez et al, 1997; Fernandez et al, 1998; Nichols
et al, 2005; Campbell et al, 2007; Hannaford et al, 2007; Lin et al,
2007; Kabat et al, 2008), whereas others have found no association
(Weiss et al, 1981; Bostick et al, 1994; Jacobs et al, 1994; Platz et al,
1997; Troisi et al, 1997; Levi et al, 2003; Purdue et al, 2005;
Dorjgochoo et al, 2009; Rosenblatt et al, 2009). A recent meta-
analysis, summarising the results from 7 cohort and 11 case–
control studies, reported a statistically significant 19% reduced
risk among ever users of oral contraceptives compared with never
users, although there was no clear association with increasing
duration of use (Bosetti et al, 2009). No consistent association has
been observed for menstrual and reproductive variables and risk of
colorectal cancer (Weiss et al, 1981; Potter and McMichael, 1983;
Peters et al, 1990; Wu-Williams et al, 1991; Gerhardsson de
Verdier and London, 1992; Bostick et al, 1994; Jacobs et al, 1994;
Kampman et al, 1997; Martinez et al, 1997; Platz et al, 1997;
Talamini et al, 1998; Nichols et al, 2005; Purdue et al, 2005; Lin
et al, 2007; Sakauchi, 2007; Akhter et al, 2008; Kabat et al, 2008;
Rosenblatt et al, 2009), although the majority of the studies are
case–control or small cohort studies with low power to study
dose–response associations.
We examined the associations of oral contraceptive use and
reproductive variables with colorectal cancer risk in the large
European Prospective Investigation into Cancer and Nutrition
(EPIC) cohort.
MATERIALS AND METHODS
Study participants included 1878 female colorectal cancer cases
(1295 colon and 583 rectal cancers) and 335924 female non-cases
recruited into EPIC, a prospective cohort that was established in
the 1990s in 10 European countries with more than half a million
participants, mostly aged 35–70 years. Incident cancer cases were
identified through linkage to population cancer registries in
Denmark, Italy, The Netherlands, Norway, Spain, Sweden and
the UK, or with a combination of methods including linkage to
health insurance records, cancer and pathology registries, and
active follow-up of study participants or their next of kin in
France, Germany and Greece. The colorectal cancer diagnosis was
confirmed by histology for 80.2% of the cases, by clinical
examination for 11.6% and the remaining 8.2% by self-report,
autopsy or death certificate. Women were excluded if they had
prevalent cancer at recruitment, if they did not return the baseline
lifestyle questionnaire, if they never menstruated or if they had
missing information on all exposure variables. Details on the
cohort population, the data collection procedures and the outcome
and covariate assessment methods have been described in detail
elsewhere (Riboli et al, 2002; Tsilidis et al, 2010).
Women were asked at the baseline questionnaire whether they
had ever used oral contraceptives, their duration of use, and age
they started use. Information on age at menarche and menopause,
numbers of full-term pregnancies (live and still births) and
induced or spontaneous abortions, age at the first full-term
pregnancy, and the reason for menopause (natural vs surgical) was
also collected. Information on breastfeeding was collected for the
first three full-term pregnancies and the last one. Menopausal
status was defined according to information on menstruation
status and ovariectomy, details of which are provided elsewhere
(Dossus et al., 2010).
Hazard ratios (HR) and their 95% confidence intervals (95% CI)
for colorectal cancer were estimated using Cox proportional
hazards models stratified by EPIC-participating center and age at
recruitment (p50, 51–53, 54–56, 57–59, 60–62, 63–65, 465
years) and adjusted for smoking status (never, former and
current), self-reported diabetes mellitus (no or yes), body mass
index (BMI; o25, X25–o30, X30kgm
 2), physical activity
(inactive, moderately inactive, moderately active, active, and
alcohol intake (quartiles: o0.58, X0.58–o3.61, X3.61–o11.08,
X11.08 g per day). Missing values for smoking status (2.2%),
diabetes (4.2%), physical activity (13.4%) and alcohol (0.8%) were
included as a separate category in the models. An analysis that
excluded women with missing values for these covariates provided
very similar results, and these are not presented here. Further
adjustment for menopausal hormone therapy, waist and hip
circumference, waist to hip ratio, dietary variables (intakes of
energy, saturated fat, fibre, folate, calcium and red meat) or mutual
adjustment for oral contraceptive use and reproductive factors in
relevant models gave virtually identical results. Analyses were also
performed according to EPIC country, cancer subsite (colon
vs rectum) and potentially modifying factors (age at recruitment
(at the median, o51 vs X51 years), BMI (o25 vs X25kgm
 2),
menopausal hormone therapy (ever vs never) and menopausal
status (post- vs pre-/peri-menopausal)).
RESULTS
The mean ages at recruitment and diagnosis for the colorectal
cancer cases were 57 and 63 years, respectively, and the mean
length of follow-up in the whole cohort was 9 years. Compared
Table 1 Participant characteristics at recruitment among women in the
European Prospective Investigation into Cancer and Nutrition cohort
Characteristic
Colorectal cancer
cases (n¼1878)
Non-cases
(n¼335924)
Mean (s.d.) age at recruitment (years) 57.4 (8.0) 50.5 (9.7)
Mean (s.d.) body mass index (kgm
 2) 25.5 (4.5) 25.0 (4.5)
Mean (s.d.) alcohol intake
(g per day)
a
10 (13.7) 9.0 (12.2)
Moderately active/active (%) 31.7 34.2
Current smokers (%) 18.5 19.6
Self-reported diabetes mellitus (%) 3.0 2.3
Menopausal status (%)
Pre-menopausal 11.2 34.2
Peri-menopausal/unknown 14.7 18.8
Post-menopausal (natural/surgical) 74.1 47.0
Ever oral contraceptive use (%) 43.8 58.4
Mean (s.d.) duration of oral
contraceptive use (years)
b
9.2 (9.8) 8.7 (9.3)
Mean (s.d.) age at menarche (years) 13.2 (1.6) 13.1 (1.5)
Mean (s.d.) age at menopause (years)
c 49.1 (4.9) 48.6 (5.1)
Ever had a full-term pregnancy (%) 83.5 79.6
Mean (s.d.) number of full-term
pregnancies
d
2.4 (1.1) 2.3 (1.0)
Mean (s.d.) age at first full-term
pregnancy, years
d
25.0 (4.4) 24.8 (4.4)
Ever breastfed (%)
d 81.2 81.8
aAmong consumers only; 8.8% of the cases and 9.2% of the non-cases were
non-consumers of alcohol.
bAmong ever oral contraceptive users only.
cAmong
post-menopausal women only.
dAmong women with a full-term pregnancy only.
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European Prospective Investigation into Cancer and Nutrition cohort
Variable Number of cases/non-cases
a Age and center-stratified, HR (95% CI) Multivariable adjusted, HR (95% CI)
b
Oral contraceptive use
Never 1040/138359 1.00 (reference) 1.00 (reference)
Ever 822/196040 0.93 (0.84–1.03) 0.92 (0.83–1.02)
Oral contraceptive use (among post-menopausal women)
Never 908/89064 1.00 (reference) 1.00 (reference)
Ever 469/67757 0.85 (0.75–0.96) 0.84 (0.74–0.95)
Oral contraceptive use (among pre-/peri-menopausal women)
Never 132/49295 1.00 (reference) 1.00 (reference)
Ever 353/128283 1.22 (0.99–1.51) 1.19 (0.96–1.48)
P-interaction o0.01 o0.01
Duration of oral contraceptive use (years)
c
p1 161/36175 1.00 (reference) 1.00 (reference)
2–4 167/42208 0.99 (0.80–1.24) 0.99 (0.80–1.23)
5–9 150/42409 0.94 (0.75–1.18) 0.93 (0.74–1.17)
X10 264/58041 1.10 (0.90–1.36) 1.09 (0.89–1.35)
P-trend 0.37 0.41
Age at menarche
o12 258/49935 1.00 (reference) 1.00 (reference)
12 358/70982 0.95 (0.81–1.11) 0.95 (0.81–1.12)
13 457/85998 0.96 (0.83–1.12) 0.97 (0.84–1.14)
14 424/71912 0.95 (0.82–1.12) 0.97 (0.83–1.14)
X15 352/52954 0.95 (0.80–1.12) 0.96 (0.82–1.14)
P-trend 0.64 0.80
Age at menopause
d
p50 654/77482 1.00 (reference) 1.00 (reference)
51–52 200/20489 1.06 (0.90–1.25) 1.07 (0.91–1.25)
53–55 196/18391 1.06 (0.90–1.25) 1.07 (0.91–1.26)
455 59/5084 0.99 (0.76–1.30) 1.00 (0.76–1.31)
P-trend 0.58 0.54
Type of menopause
d
Natural 1303/147920 1.00 (reference) 1.00 (reference)
Surgical 88/9875 1.14 (0.91–1.42) 1.13 (0.91–1.41)
Induced or spontaneous abortion
Never 1129/180995 1.00 (reference) 1.00 (reference)
Ever 221/45509 1.01 (0.87–1.18) 1.00 (0.86–1.17)
Full-term pregnancy
Never 231/49342 1.00 (reference) 1.00 (reference)
Ever 1568/267467 0.96 (0.83–1.10) 0.96 (0.83–1.10)
Number of full-term pregnancies
e
1 250/49177 1.00 (reference) 1.00 (reference)
2 721/129409 1.16 (1.00–1.34)) 1.16 (1.01–1.35)
3 384/61490 1.15 (0.98–1.36) 1.16 (0.98–1.36)
X4 213/27391 1.17 (0.97–1.41) 1.17 (0.97–1.42)
P-trend 0.15 0.15
Age at first full-term pregnancy
e
p20 210/40007 1.00 (reference) 1.00 (reference)
21–23 433/71912 1.01 (0.86–1.19) 1.02 (0.86–1.21)
24–25 320/52140 0.97 (0.81–1.16) 0.98 (0.82–1.18)
26–30 439/75488 0.90 (0.76–1.07) 0.92 (0.77–1.09)
430 163/26886 0.98 (0.79–1.20) 0.99 (0.80–1.22)
P-trend 0.22 0.30
Breastfeeding
e
Never 211/39471 1.00 (reference) 1.00 (reference)
Ever 1273/218695 1.12 (0.97–1.31) 1.13 (0.97–1.32)
aThe number of cases and non-cases do not add up to the total number of 1878 cases and 335924 non-cases because of missing values.
bFrom a Cox proportional hazards model
stratified by the European Prospective Investigation into Cancer and Nutrition participating center and age at recruitment, and adjusted for smoking status (never, former, current),
diabetes mellitus (never, ever), body mass index (o25, X25–o30, X30kgm
 2), physical activity (inactive, moderately inactive, moderately active, active), and alcohol use (o0.58,
X0.58–o3.61, X3.61–o11.08, X11.08g per day).
cAmong ever oral contraceptive users only.
dAmong post-menopausal women only.
eAmong women with a full-term pregnancy.
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older, had slightly higher BMI, drank more alcohol, exercised
less and were less likely to have ever taken oral contraceptives
(Table 1).
Overall, there were no statistically significant associa-
tions between oral contraceptives, reproductive factors
and colorectal cancer risk (Table 2). Ever use of oral contracep-
tives was marginally inversely associated with risk (HR, 0.92;
95% CI: 0.83–1.02), but neither duration of use (P-trend, 0.41) nor
age at start of use (P-trend, 0.32) were associated with risk.
However, the association of oral contraceptive use on risk varied
by menopausal status (P-interaction, o0.01); ever use of
oral contraceptives was associated with a significantly reduced
risk in post-menopausal women (HR, 0.84; 95% CI: 0.74–0.95),
but no significant association was observed among pre- or
peri-menopausal women (HR, 1.19; 95% CI: 0.96–1.48). There
was no evidence of an interaction for duration or age at start
of oral contraceptive use by menopausal status (data not
shown).
Reproductive factors, including age at menarche, age at
menopause, type of menopause, ever having an abortion, parity,
age at first full-term pregnancy and breastfeeding, were not
associated with colorectal cancer risk (Table 2). The associations
between oral contraceptive use, reproductive factors and colorectal
cancer risk did not differ according to country, colorectal cancer
subsite and baseline characteristics (age, BMI, menopausal
hormone therapy and menopausal status).
DISCUSSION
In this large prospective study, ever use of oral contraceptives was
associated with a small reduction in colorectal cancer risk, which
was stronger among post-menopausal women compared with
pre-/peri-menopausal women. Although our finding of an inverse
association with use of oral contraceptives is consistent with the
prior literature (Bosetti et al, 2009), most studies have not reported
a reduction in colorectal cancer risk with increasing duration of
oral contraceptive use (Bosetti et al, 2009). This may, in part, be
because of relatively small study sizes to detect a significant
association, although the present study, with over 1800 cases, also
found no association with duration of oral contraceptive use. Our
stronger inverse finding for oral contraceptive use and colorectal
cancer risk in post-menopausal women did not change after
adjustment for menopausal hormone therapy and reproductive
variables, and is not explained by a longer duration of oral
contraceptive use among older women as there was no association
between duration of use and risk overall or in subgroups by
menopausal status. In addition, post-menopausal women had only
a slightly longer mean duration of oral contraceptive use compared
with pre-/peri-menopausal women (9.1 vs 8.5 years), despite being
older at recruitment (58 vs 44 years). However, post-menopausal
women were more likely to have started using oral contraceptives
during the 1960s when high-dose formulations were much more
common (McMichael and Potter, 1980), which may partly explain
the apparent higher risk in these women. Earlier studies have not
reported significant interactions between oral contraceptive use
and colorectal cancer risk by age or menopausal status (Kampman
et al, 1997; Lin et al, 2007); however, one case–control study
observed a non-significant reduced risk of colon cancer for
ever use of oral contraceptives among women older than 62 years
at recruitment, and no association among younger women
(Kampman et al, 1997). Future studies with detailed infor-
mation on the dose and hormonal constituent of the oral
contraceptives are needed to clarify this association. No significant
associations were found for reproductive factors, which is
consistent with most of the literature (Gerhardsson de Verdier
and London, 1992; Kampman et al, 1997; Troisi et al, 1997; Nichols
et al, 2005; Lin et al, 2007; Sakauchi, 2007; Akhter et al, 2008; Kabat
et al, 2008).
The major strength of this study is its size and power to study
dose-response associations, and its detailed and standardised
assessment of reproductive factors across Europe. In conclusion,
oral contraceptive use was associated with a reduced risk of
colorectal cancer among post-menopausal women. Duration of
oral contraceptive use and reproductive factors were not
associated with risk. Our findings provide limited support for a
potential inverse association between oral contraceptives and
colorectal cancer risk.
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